Pharmanovia to boost investment in nation
5 months ago

Pharmanovia to boost investment in nation

China Daily  

With plenty of opportunities, China is expected to grow faster than other markets for United Kingdom-based global pharmaceutical company Pharmanovia, said a senior executive in an exclusive interview in Shanghai on Friday. Such continuous growth comes after China had already been the drugmaker's No 1 market globally since 2023, accounting for roughly 25 percent of the company's total sales, said James Burt, CEO of Pharmanovia, which was founded in 2013 and started business in China in 2018. Jin Chunlin, director of the Shanghai Municipal Health Development Research Center, said the aging process in China and the increasing demand for the treatment of major and rare diseases have also made the market more attractive for innovative drugs, which attracts domestic and foreign pharmaceutical firms alike. "China's new drug approval and public medical insurance policies have been inclined to support truly innovative pharmaceutical companies in recent years.

History of this topic

Chinese-made new drugs big hit overseas
5 months ago
Chinese-made new drugs big hit overseas
5 months ago
Drug giants eye China for deals despite growing Sino-US tensions
5 months ago
Guideline promotes pharma innovation
5 months, 1 week ago
Guideline promotes pharma innovation
5 months, 1 week ago
Pharma perfect match for China's new forces
8 months, 3 weeks ago
Pharma perfect match for China's new forces
8 months, 3 weeks ago
Indian pharma industry must focus on innovation, say industry leaders
1 year, 10 months ago
Foreign pharma firms upbeat on China
3 years, 8 months ago
Multinationals see huge development opportunities in nation's opening-up
4 years ago

Discover Related